BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach
BYSI•Investor deck highlights plinabulin program
BeyondSpring highlighted plinabulin as a late-stage immune modulator positioned for 2L/3L NSCLC, including post–PD-1/L1 progression.
- DUBLIN-3 Phase 3 (n=559) met its primary endpoint, showing OS HR 0.82; median OS was 10.5 months vs 9.4 months.
- Trial data also showed PFS and ORR improvements; grade 4 neutropenia fell sharply, including 33.58% to 5.13% on day 8.
- The company outlined DUBLIN-4, a confirmatory Phase 3 in non-squamous EGFR, ALK, ROS1, RET WT NSCLC post-immunotherapy; global N=442; primary endpoint OS.
- Study 303 in post-ICI metastatic NSCLC (n=47) reported confirmed ORR 18.2%; median PFS 7.0 months; 24-month OS 58%.
